BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.
BiohacksAI is an evolving research platform. New compounds and evidence are added continuously.
B
CONDITION

Evidence-Based Compounds for Depression

Depression involves disrupted monoamine signalling, neuroinflammation, impaired neuroplasticity, and HPA axis dysregulation. Multiple natural compounds show clinical evidence for improving depressive symptoms through serotonin reuptake modulation, BDNF upregulation, anti-inflammatory action, and cortisol normalisation — with growing evidence from RCTs.

Top 6 Compounds — Ranked by Evidence
Weighted ranking: BiohacksAI discovery score · pathway overlap · PubMed study count
Ranking Methodology
Compounds are ranked using a four-signal weighted model: BiohacksAI discovery score (cross-study convergence across targets), target match (direct overlap with SLC6A4, BDNF, MAOA and related targets — highest differentiating signal), pathway overlap with DOPAMINE SEROTONIN and NEUROTROPHIC pathways, and PubMed study count (log-scaled). Clinical drugs are excluded.
Key Biological Targets

Click a target to see all compounds with documented interactions in the BiohacksAI corpus.

This page presents computational analysis of published research from PubMed/NCBI, BindingDB, and Reactome. Rankings are based on BiohacksAI discovery score, pathway overlap, and study count. This is not medical advice — consult a healthcare professional before starting any supplement.

Browse all compounds · Biological pathways · Molecular targets · All conditions

© Organiq Sweden AB · Patent pending EVE-PAT-2026-001